| |
Ovarian cancer
|
Crude HR (95% CI)
|
Adjusted HR† (95% CI)
|
|---|
|
Event
|
PY
|
IR
|
|---|
|
Pelvic inflammatory disease
|
168
|
613,316
|
0.27
|
1.67 (1.36–2.05)***
|
1.49 (1.21–1.84)***
|
|
Age, years
| | | | | |
|
< 20
|
11
|
123,291
|
0.08
|
1 (reference)
|
1 (reference)
|
|
20–30
|
62
|
559,564
|
0.11
|
1.24 (0.65–2.36)
|
1.16 (0.61–2.22)
|
|
30–40
|
109
|
545,092
|
0.19
|
2.26 (1.21–4.20)**
|
1.98 (1.04–3.78)*
|
|
40–50
|
121
|
403,108
|
0.30
|
3.38 (1.82–6.27)***
|
3.01 (1.57–5.75)***
|
|
50–60
|
42
|
125,894
|
0.33
|
3.71 (1.91–7.21)***
|
3.32 (1.66–6.64)***
|
|
≥ 60
|
20
|
57,330
|
0.34
|
3.82 (1.83–7.97)***
|
3.31 (1.54–7.10)**
|
|
Comorbidity
| | | | | |
|
Lynch syndrome and colon cancer
|
4
|
1200
|
3.33
|
16.1 (6.01–43.1)***
|
5.47 (1.48–20.1)*
|
|
Breast cancer
|
4
|
6104
|
0.65
|
3.20 (1.19–8.57)*
|
1.93 (1.03–5.23)*
|
|
Uterus cancer
|
5
|
832
|
6.00
|
25.5 (11.8–69.0)***
|
13.9 (5.70–34.2)***
|
|
Rectum cancer
|
3
|
864
|
3.47
|
16.6 (5.33–51.7)***
|
3.25 (0.72–14.6)
|
|
Endometriosis
|
41
|
54,969
|
0.74
|
3.97 (2.87–5.49)***
|
2.93 (2.09–4.12)***
|
|
Infertility
|
25
|
59,497
|
0.42
|
2.15 (1.43–3.23)***
|
1.84 (1.21–2.80)**
|
|
Obesity
|
3
|
10,516
|
0.28
|
1.38 (0.44–4.30)
|
1.09 (0.35–3.40)
|
|
Monthly income (NTD)
| | | | | |
|
< 15,000
|
130
|
836,290
|
0.15
|
1 (reference)
|
1 (reference)
|
|
15,000–29,999
|
189
|
763,730
|
0.24
|
1.62 (1.29–2.02)***
|
1.13 (0.89–1.43)
|
|
≥ 30,000
|
46
|
214,260
|
0.21
|
1.40 (1.00–1.97)*
|
0.98 (0.69–1.39)
|
- PID pelvic inflammatory disease, HR hazard ratio, PY person-years, IR incidence rate per 1000 person-years, CI confidence interval, NTD New Taiwan dollar
- †HR adjusted for age, Lynch syndrome and colon cancer, breast cancer, uterus cancer, rectum cancer, endometriosis, infertility, obesity, and monthly income
- *P < 0.05, **P < 0.01, ***P < 0.001, versus the reference group
